Chemically edited molecular glue in action: How 12-deoxyfusicoccin locks a repressor

A novel study uncovers how a subtle chemical tweak transforms the naturally occurring phytotoxin into a powerful molecular ...

Cell-free Protein Synthesis Market Research and Global Forecast Report 2025-2030: Integration Into Next-Generation Diagnostics and Sensing Platforms Drive Adoption

The cell-free protein synthesis (CFPS) market is set to reach USD 308.9 million by 2030, growing at a CAGR of 7.3%. Key growth drivers include rising demand for rapid protein production, adoption of ...

Ginkgo - OpenAI collaboration cuts costs in protein synthesis

Ginkgo Bioworks (DNA) stock is in focus as the company as part of a collaboration with Microsoft (MSFT)-backed OpenAI cuts protein synthesis costs. Read more here.
TMCnet

Ginkgo Bioworks' Autonomous Laboratory Driven by OpenAI's GPT-5 Achieves 40% Improvement Over State-of-the-Art Scientific Benchmark

Preprint describes how GPT-5-driven autonomous lab significantly reduced reaction costs in cell-free protein synthesis Ginkgo ...
FierceBiotech

Rewriting Cellular Communication: Advances in Synthetic Biology through Enzymatic DNA Synthesis for Protein Regulation

In recent years, mammalian synthetic biology has made significant strides, especially in controlling gene expression and designing complex cellular behaviors. Researchers have now begun to apply these ...
GEN

Lactose-Eating Yeast Boosts Yields and Cuts Costs for Cell-Free Protein Synthesis

The yeast Kluyveromyces lactis (K. lactis) could become a highly productive, sustainable, cost-effective energy source for cell-free protein synthesis (CFPS) as biopharmaceutical manufacturers strive ...

Ginkgo, OpenAI Cut Protein Costs by 40%

Ginkgo Bioworks says a new AI collaboration with OpenAI is already paying off, cutting the cost of protein production in the lab by a mea ...
OfficeChai

OpenAI Connected GPT-5 To An Autonomous Lab To Conduct Experiments, System Brought Down Protein Production Cost By 40%

It had been thought that AI would play a big part in digital-only domains like math and coding, but cleverly connecting these ...
The Scientist

Cell-Free DNA: Accelerating Next-Gen mRNA Therapeutics

Galit Meshulam-Simon is the associate director of Commercial Applications at Elegen. COVID-19 brought messenger RNA (mRNA) into the global spotlight, demonstrating its speed, flexibility, and efficacy ...